• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Repurposing and re-positioning of old treatments for new indications: A focus on addictive disorders

    Author(s)
    MacDonald, Tim
    Griffith University Author(s)
    MacDonald, Tim S.
    Year published
    2018
    Metadata
    Show full item record
    Abstract
    Introduction and Aims There are a plethora of biomedical treatments used in mainstream medical practice, for many well‐known diagnoses, some dating back for centuries. Despite the aging of most populations worldwide and the increasing global burdens of various diseases in recent decades, there has been a relative paucity in development of new treatments for neuropsychiatric conditions in particular. This is potentially due to big pharma retreating, microeconomic and macroeconomic constraints and the fastidious process of developing and then testing new molecules or treatments on a complex human brain. The benefits of ...
    View more >
    Introduction and Aims There are a plethora of biomedical treatments used in mainstream medical practice, for many well‐known diagnoses, some dating back for centuries. Despite the aging of most populations worldwide and the increasing global burdens of various diseases in recent decades, there has been a relative paucity in development of new treatments for neuropsychiatric conditions in particular. This is potentially due to big pharma retreating, microeconomic and macroeconomic constraints and the fastidious process of developing and then testing new molecules or treatments on a complex human brain. The benefits of psychological, behavioural, mutual help and other treatments are generally well known and accepted; however, limitations for their use exist also. The author aims to summarise how some older medications are being used for new indications, in particular relating to addictive disorders. Design and Methods A précis of relevant literature and anecdotes is presented. The author presents an opinion on current trends in ‘off label’ medication use, and offer a glimpse into potential future applications. Results Numerous novel ways of repurposing treatments were discovered, including oxytocin for alcohol use disorder, lisdexamfetamine for stimulant use disorder and N‐acetyl cysteine for cannabis use disorder. A case series on subcutaneous flumazenil infusions for benzodiazepine use disorder was outlined. Discussion and Conclusions The modern era of medicine comes with it hope but also a degree of constriction which conflates to drive flexible and creative ways of treating refractory conditions. Amongst addictive disorders alone, there are a number of potentially beneficial repositioned treatments for which little or no research/consensus exists. The reasons driving a request (or behest), acceptance or reluctance to trial old approaches for novel reasons is often not congruent with evidence or based on biological plausibility. The scope for further research with many of these treatments is limited due to lack of financial incentives, but potentially less onerous if safety has been established in previous Phase I and II trials for other conditions. Disclosure of Interest Statement The author declares no conflict of interests related to this manuscript. TM has received honoraria, fees and/or provision of professional development resources from Servier, Otsuka/Lundbeck, Australian and New Zealand Mental Health Association, and Healthe Care. He works in the private sector and receives income for clinical services provided.
    View less >
    Conference Title
    Drug and Alcohol Review
    Volume
    37
    Issue
    S3
    Publisher URI
    https://onlinelibrary.wiley.com/doi/10.1111/dar.12862
    Subject
    Medical and Health Sciences
    Studies in Human Society
    Psychology and Cognitive Sciences
    Science & Technology
    Life Sciences & Biomedicine
    Substance Abuse
    Publication URI
    http://hdl.handle.net/10072/402273
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander